Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita

Bone Marrow Transplant. 2016 May;51(5):744-6. doi: 10.1038/bmt.2015.333. Epub 2016 Jan 25.

Authors

M Brown¹, D Myers², N Shreve², R Rahmetullah², M Radhi²

Affiliations

¹ Department of Pediatrics, University of Missouri Kansas City-School of Medicine, Kansas City, MO, USA.
² Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.

PMID: 26808569
DOI: 10.1038/bmt.2015.333

No abstract available

Publication types

Case Reports

MeSH terms

Alemtuzumab / administration & dosage*
Bone Marrow / pathology
Child
Cord Blood Stem Cell Transplantation*
Cyclophosphamide / administration & dosage*
Dyskeratosis Congenita / therapy*
Graft Survival
Hematopoietic Stem Cell Transplantation*
Heterozygote
Humans
Immunosuppressive Agents / administration & dosage
Male
Mutation
Transplantation Conditioning / methods*
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives*
Whole Body Imaging

Substances

Immunosuppressive Agents
Alemtuzumab
Cyclophosphamide
Vidarabine
fludarabine